Genomic sequencing Examination of 733 HER2-amplified Main and metastatic breast tumours unveiled substantial enrichment of mutations that activate RAS–MAPK signalling in Highly developed tumours handled with prior anti-HER2 therapies121. These mutations, which include NF1 and HER2 activating mutations, contribute to resistance to tucatinib and neratinib. Straightforward or full mastec... https://www.directivepublications.org/journal-of-clinical-breast-cancer/